Skip to main content
SpringerLink
Log in
Book cover

Prostate Cancer Prevention pp 93–100Cite as

Aspirin and Prostate Cancer Prevention

  • Chapter
  • First Online:

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 202))

Abstract

Aspirin has been associated to a reduced risk of colorectal, and possibly of other cancers. Data from at least 25 observational studies also suggest a modest reduced risk of prostate cancer in regular aspirin users, with a summary relative risk, RR, of 0.91 (95 % confidence interval, CI, 0.86–0.96) overall, 0.87 (95 % CI 0.74–1.02) from nine case–control studies, and 0.92 (95 % CI 0.87–0.97) from 16 cohort studies. However, risk estimates are heterogeneous and there is no relation with frequency, dose, or duration of aspirin use. Data from randomized controlled trials of aspirin for the prevention of vascular events showed a nonsignificant reduced risk of death from prostate cancer after a latent period of five or more years (RR 0.52, 95 % CI 0.20–1.24) based on 37 deaths from prostate cancer from seven trials. The RR was 0.81 (95 % CI 0.61–1.06) after 20 years of follow-up, based on 210 cases from three trials with long-term follow-up. Thus, data from observational studies and clinical trials are compatible with a modest favorable effect of aspirin on prostate cancer. Inference for causality and public health implications are, however, far from conclusive given the heterogeneity of results and the lack of dose and duration-risk relationships. Data on prostate cancer survival are still limited and inconsistent.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Algra AM, Rothwell PM (2012) Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 13(5):518–527

    Article  CAS  PubMed  Google Scholar 

  • Bambace NM, Holmes CE (2011) The platelet contribution to cancer progression. J Thromb Haemost 9(2):237–249

    Article  CAS  PubMed  Google Scholar 

  • Bosetti C, Talamini R, Negri E, Franceschi S, Montella M, La Vecchia C (2006) Aspirin and the risk of prostate cancer. Eur J Cancer Prev 15(1):43–45

    Article  CAS  PubMed  Google Scholar 

  • Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C (2012a) Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 23(6):1403–1415

    Article  CAS  PubMed  Google Scholar 

  • Bosetti C, Rosato V, Gallus S, La Vecchia C (2012b) Aspirin and urologic cancer risk: an update. Nat Rev Urol 9(2):102–110

    Article  CAS  PubMed  Google Scholar 

  • Brown JR, DuBois RN (2005) COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 23(12):2840–2855

    Article  CAS  PubMed  Google Scholar 

  • Camerer E, Qazi AA, Duong DN, Cornelissen I, Advincula R, Coughlin SR (2004) Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 104(2):397–401

    Article  CAS  PubMed  Google Scholar 

  • Choe KS, Cowan JE, Chan JM, Carroll PR, D’Amico AV, Liauw SL (2012) Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol 30(28):3540–3544

    Article  CAS  PubMed  Google Scholar 

  • Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P et al (2009) Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10(5):501–507

    Article  CAS  PubMed  Google Scholar 

  • Dasgupta K, Di Cesar D, Ghosn J, Rajan R, Mahmud S, Rahme E (2006) Association between nonsteroidal anti-inflammatory drugs and prostate cancer occurrence. Cancer J 12(2):130–135

    CAS  PubMed  Google Scholar 

  • Dhillon PK, Kenfield SA, Stampfer MJ, Giovannucci EL (2011) Long-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988–2006. Int J Cancer 128(10):2444–2452

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Dhillon PK, Kenfield SA, Stampfer MJ, Giovannucci EL, Chan JM (2012) Aspirin use after a prostate cancer diagnosis and cancer survival in a prospective cohort. Cancer Prev Res (Phila) 5(10):1223–1228

    Article  CAS  Google Scholar 

  • Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G (2009) Aspirin, salicylates, and cancer. Lancet 373(9671):1301–1309

    Article  CAS  PubMed  Google Scholar 

  • Garcia Rodriguez LA, Gonzalez-Perez A (2004) Inverse association between nonsteroidal anti-inflammatory drugs and prostate cancer. Cancer Epidemiol Biomarkers Prev 13(4):649–653

    Google Scholar 

  • Gay LJ, Felding-Habermann B (2011) Contribution of platelets to tumour metastasis. Nat Rev Cancer 11(2):123–134

    Article  CAS  PubMed  Google Scholar 

  • Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H (2000) Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42(1):73–78

    Article  CAS  PubMed  Google Scholar 

  • Habel LA, Zhao W, Stanford JL (2002) Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Control 13(5):427–434

    Article  Google Scholar 

  • Harris RE, Beebe-Donk J, Alshafie GA (2007) Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade (Chapter 9). In: Harris RE (ed) Inflammation in the pathogenesis of chronic diseases. Springer, New York, pp 193–212

    Google Scholar 

  • Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE (2007) A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 99(8):608–615

    Article  CAS  PubMed  Google Scholar 

  • Jacobs EJ, Newton CC, Gapstur SM, Thun MJ (2012) Daily aspirin use and cancer mortality in a large US cohort. J Natl Cancer Inst 104(16):1208–1217

    Article  CAS  PubMed  Google Scholar 

  • Langley RE, Burdett S, Tierney JF, Cafferty F, Parmar MK, Venning G (2011) Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? Br J Cancer 105(8):1107–1113

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Liu X, Plummer SJ, Nock NL, Casey G, Witte JS (2006) Nonsteroidal antiinflammatory drugs and decreased risk of advanced prostate cancer: modification by lymphotoxin alpha. Am J Epidemiol 164(10):984–989

    Article  PubMed  Google Scholar 

  • Mahmud SM, Franco EL, Aprikian AG (2010) Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int J Cancer 127(7):1680–1691

    Article  CAS  PubMed  Google Scholar 

  • Mahmud SM, Franco EL, Turner D, Platt RW, Beck P, Skarsgard D et al (2011) Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested case-control study. PLoS ONE 6(1):e16412

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Menezes RJ, Swede H, Niles R, Moysich KB (2006) Regular use of aspirin and prostate cancer risk (United States). Cancer Control 17(3):251–256

    Article  Google Scholar 

  • Perron L, Bairati I, Moore L, Meyer F (2003) Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. Int J Cancer 106(3):409–415

    Article  CAS  PubMed  Google Scholar 

  • Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377(9759):31–41

    Article  CAS  PubMed  Google Scholar 

  • Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G et al (2012a) Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379(9826):1602–1612

    Article  CAS  PubMed  Google Scholar 

  • Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z (2012b) Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379(9826):1591–1601

    Article  CAS  PubMed  Google Scholar 

  • Salinas CA, Kwon EM, FitzGerald LM, Feng Z, Nelson PS, Ostrander EA et al (2010) Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. Am J Epidemiol 172(5):578–590

    Article  PubMed  Google Scholar 

  • Taketo MM (1998a) Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 90(20):1529–1536

    Article  CAS  PubMed  Google Scholar 

  • Taketo MM (1998b) Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J Natl Cancer Inst 90(21):1609–1620

    Article  CAS  PubMed  Google Scholar 

  • Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94(4):252–266

    Article  CAS  PubMed  Google Scholar 

  • Veitonmäki T, Tammela TL, Auvinen A, Murtola TJ (2013) Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. Eur J Cancer 49(4):938–945

    Article  PubMed  Google Scholar 

  • Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Chargui J et al (2000) Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 89(3):589–596

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was conducted with the contribution of the Italian Association for Cancer Research (grant No. 10068).

Author information

Authors and Affiliations

  1. Department of Epidemiology, IRCCS—Istituto di Ricerche Farmacologiche “Mario Negri”, Via La Masa 19, 20156, Milan, Italy

    Cristina Bosetti, Valentina Rosato, Silvano Gallus & Carlo La Vecchia

  2. Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy

    Carlo La Vecchia

Authors
  1. Cristina Bosetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Valentina Rosato
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Silvano Gallus
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carlo La Vecchia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cristina Bosetti .

Editor information

Editors and Affiliations

  1. Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine Queen Mary University of London, London, United Kingdom

    Jack Cuzick

  2. Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine Queen Mary University of London, London, United Kingdom

    Mangesh A. Thorat

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Bosetti, C., Rosato, V., Gallus, S., La Vecchia, C. (2014). Aspirin and Prostate Cancer Prevention. In: Cuzick, J., Thorat, M. (eds) Prostate Cancer Prevention. Recent Results in Cancer Research, vol 202. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-45195-9_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-45195-9_11

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-45194-2

  • Online ISBN: 978-3-642-45195-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation